NLS lipigon

Lipigon Pharmaceuticals has signed agreements with the two universities to develop a new drug that can potentially reduce the number of deaths linked to COVID-19. The Umeå-based company has signed an agreement with Nanyang Technological University in Singapore and Shenzhen to test whether one of its drug candidates, which blocks a protein that is very […]

Lipigon Pharmaceuticals has signed a new agreement with Chinese biotech company HitGen to develop drug candidates that treat blood fat disorders and cardiovascular diseases. Lipigon, which is located at the Umeå Biotech Incubator, specializes in developing medicines for lipid-related disorders, i.e. diseases caused by irregularities when fats are processed in the body. HitGen is a […]

Lipigon acquires antisense drug candidates for cardiovascular and metabolic diseases from Secarna. The company has acquired antisense drug candidates jointly generated with Secarna Pharmaceuticals under a previous research collaboration. Lipigon will continue the research and development of the acquired assets targeting the ANGPTL gene family, and Secarna will receive undisclosed payments customary for such a […]

Lipigon Pharmaceuticals has entered into a Target Validation Research Agreement with the German antisense therapeutics company Secarna Pharmaceuticals. The goal is to co-develop a drug for treatment of severe forms of dyslipidemia and related lipid disorder driven diseases. “We are very pleased for this exciting opportunity to work together with Secarna, bringing forward what we […]

The spin-off company, and Umeå Biotech Incubator project, Lipigon Pharmaceuticals and AstraZeneca have entered a research collaboration to develop a high throughput assay for the identification of molecules against elevated blood lipids. Lipoprotein lipase (LPL) is a promising target for development of new medicines for dyslipidemia and other cardiometabolic risk markers. Recent evidence from genetic- […]